EU Ban on Drugmaker-Patient Communication Under Review
This article is for subscribers only.
European Union restrictions on pharmaceutical companies communicating directly with patients will be reviewed by regulators planning new draft rules, EU officials said.
The European Medicines Agency received a letter from the Polish presidency of the EU’s Council of Ministers saying that it will review the policy, said Peter Arlett, head of the agency’s drug safety unit, at a meeting in London today. The rules are intended to make regulations more uniform across the 27-nation bloc.